S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:ZNTL

Zentalis Pharmaceuticals Stock Forecast, Price & News

$42.33
-1.22 (-2.80 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.80
Now: $42.33
$44.15
50-Day Range
$35.69
MA: $41.22
$50.92
52-Week Range
$22.00
Now: $42.33
$61.29
Volume481,759 shs
Average Volume270,280 shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York.
Zentalis Pharmaceuticals logo

Headlines

Why Earnings Season Could Be Great for Zentalis (ZNTL)
February 4, 2021 |  finance.yahoo.com
ZNTL Crosses Above Average Analyst Target
December 23, 2020 |  nasdaq.com
Is ZNTL A Good Stock To Buy Now?
December 12, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZNTL
CUSIPN/A
CIKN/A
Phone212-433-3791
Employees110
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.72 billion
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

417th out of 1,972 stocks

Pharmaceutical Preparations Industry

202nd out of 772 stocks

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$42.33
-1.22 (-2.80 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZNTL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zentalis Pharmaceuticals (NASDAQ:ZNTL) Frequently Asked Questions

Is Zentalis Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zentalis Pharmaceuticals stock.
View analyst ratings for Zentalis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Zentalis Pharmaceuticals?

Wall Street analysts have given Zentalis Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zentalis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zentalis Pharmaceuticals' next earnings date?

Zentalis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Zentalis Pharmaceuticals
.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) posted its earnings results on Monday, November, 9th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.17.
View Zentalis Pharmaceuticals' earnings history
.

What price target have analysts set for ZNTL?

7 equities research analysts have issued 12-month target prices for Zentalis Pharmaceuticals' shares. Their forecasts range from $41.00 to $75.00. On average, they expect Zentalis Pharmaceuticals' share price to reach $51.14 in the next twelve months. This suggests a possible upside of 20.8% from the stock's current price.
View analysts' price targets for Zentalis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Zentalis Pharmaceuticals' key executives?

Zentalis Pharmaceuticals' management team includes the following people:
  • Dr. Anthony Y. Sun M.D., Pres, CEO & Exec. Chairman (Age 49, Pay $659.88k)
  • Dr. Kevin D. Bunker Ph.D., Chief Operating Officer (Age 49, Pay $504.03k)
  • Mr. Cam S. Gallagher M.B.A., Sec. & Director (Age 51, Pay $226.04k)
  • Ms. Melissa B. Epperly M.B.A., Chief Financial Officer (Age 44)
  • Ms. Alexis Pinto J.D., Chief Legal Officer
  • Mr. Ahmed Samatar Ph.D., Sr. VP of Oncology Research
  • Dr. Dimitris Voliotis M.D., Sr. VP of Clinical Devel. (Age 58)
  • Dr. Peter Huang Ph.D., Sr. VP of Discovery Research

Who are some of Zentalis Pharmaceuticals' key competitors?

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).

When did Zentalis Pharmaceuticals IPO?

(ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

What is Zentalis Pharmaceuticals' stock symbol?

Zentalis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZNTL."

Who are Zentalis Pharmaceuticals' major shareholders?

Zentalis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Viking Global Investors LP (7.41%), BlackRock Inc. (5.60%), Primecap Management Co. CA (3.38%), Avidity Partners Management LP (2.79%), Price T Rowe Associates Inc. MD (2.69%) and Alliancebernstein L.P. (2.05%). Company insiders that own Zentalis Pharmaceuticals stock include Anthony Y Sun, Cam Gallagher, David Michael Johnson, Global Investors Lp Viking, Kevin D Bunker and Melissa B Epperly.
View institutional ownership trends for Zentalis Pharmaceuticals
.

Which major investors are selling Zentalis Pharmaceuticals stock?

ZNTL stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, SG Americas Securities LLC, Price T Rowe Associates Inc. MD, Primecap Management Co. CA, and Verition Fund Management LLC. Company insiders that have sold Zentalis Pharmaceuticals company stock in the last year include Anthony Y Sun, Cam Gallagher, David Michael Johnson, Global Investors Lp Viking, Kevin D Bunker, and Melissa B Epperly.
View insider buying and selling activity for Zentalis Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Zentalis Pharmaceuticals stock?

ZNTL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Avidity Partners Management LP, Northern Trust Corp, Great Lakes Advisors LLC, Morgan Stanley, Nuveen Asset Management LLC, Caas Capital Management LP, and Alliancebernstein L.P.. Company insiders that have bought Zentalis Pharmaceuticals stock in the last two years include Anthony Y Sun, David Michael Johnson, Global Investors Lp Viking, Kevin D Bunker, and Melissa B Epperly.
View insider buying and selling activity for Zentalis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zentalis Pharmaceuticals' stock price today?

One share of ZNTL stock can currently be purchased for approximately $42.33.

How much money does Zentalis Pharmaceuticals make?

Zentalis Pharmaceuticals has a market capitalization of $1.72 billion.

How many employees does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals employs 110 workers across the globe.

What is Zentalis Pharmaceuticals' official website?

The official website for Zentalis Pharmaceuticals is www.zentalis.com.

Where are Zentalis Pharmaceuticals' headquarters?

Zentalis Pharmaceuticals is headquartered at 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018.

How can I contact Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals' mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The company can be reached via phone at 212-433-3791 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.